NASDAQ:MCRB Seres Therapeutics (MCRB) Stock Price, News & Analysis $6.11 0.00 (0.00%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$6.10 -0.02 (-0.25%) As of 07/10/2026 05:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock About Seres Therapeutics Stock (NASDAQ:MCRB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Seres Therapeutics alerts:Sign Up Key Stats Today's Range$6.03▼$6.8550-Day Range$5.62▼$8.1452-Week Range$5.31▼$29.98Volume154,450 shsAverage Volume115,153 shsMarket Capitalization$59.14 millionP/E RatioN/ADividend YieldN/APrice Target$17.00Consensus RatingHold Company Overview Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted. Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection. Seres is also advancing SER-287 in ulcerative colitis, SER-401 in combination with immunotherapy for certain cancers, and other preclinical programs targeting metabolic and inflammatory diseases. The company collaborates with strategic partners, including Nestlé Health Science, to support development, manufacturing scale-up and global research efforts. Founded in 2010, Seres went public in 2015 to further accelerate its clinical pipeline. The management team comprises experienced biotech executives, clinicians and scientists with expertise in microbiome research and product development. Seres continues to conduct multi‐center clinical trials across North America and Europe, seeking to bring first‐in‐class microbiome therapies to patients with limited treatment options.AI Generated. May Contain Errors. Read More Seres Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreMCRB MarketRank™: Seres Therapeutics scored higher than 66% of companies evaluated by MarketBeat, and ranked 287th out of 853 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingHold Consensus RatingSeres Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialSeres Therapeutics has a consensus price target of $17.00, representing about 178.2% upside from its current price of $6.11.Amount of Analyst CoverageSeres Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Seres Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Seres Therapeutics are expected to grow in the coming year, from ($5.84) to ($2.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Seres Therapeutics is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Seres Therapeutics is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSeres Therapeutics has a P/B Ratio of 1.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Seres Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.71% of the float of Seres Therapeutics has been sold short.Short Interest Ratio / Days to CoverSeres Therapeutics has a short interest ratio ("days to cover") of 1.32, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Seres Therapeutics has recently decreased by 28.43%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSeres Therapeutics does not currently pay a dividend.Dividend GrowthSeres Therapeutics does not have a long track record of dividend growth. News and Social Media1.9 / 5News Sentiment0.07 News SentimentSeres Therapeutics has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Seres Therapeutics this week, compared to 2 articles on an average week. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Seres Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders5.20% of the stock of Seres Therapeutics is held by insiders.Percentage Held by Institutions59.34% of the stock of Seres Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Seres Therapeutics' insider trading history. Receive MCRB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Seres Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MCRB Stock News HeadlinesSeres Therapeutics' SER-155 posts 80% response in cancer immunotherapy GI toxicity studyJuly 11 at 5:40 PM | msn.comSeres Therapeutics Shareholders Approve Directors and Executive PayJuly 8, 2026 | tipranks.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it. | Banyan Hill Publishing (Ad)Seres Therapeutics, Inc. (MCRB) Discusses Promising SER-155 Clinical Trial Results for Immune Checkpoint Inhibitor Related Andropilatis TranscriptJuly 8, 2026 | seekingalpha.comSeres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That ...July 8, 2026 | finance.yahoo.comSeres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer TreatmentJuly 8, 2026 | globenewswire.comSeres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related EnterocolitisJune 25, 2026 | uk.finance.yahoo.comSeres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres' SER-155 in Immune Checkpoint Inhibitor-Related EnterocolitisJune 25, 2026 | globenewswire.comSee More Headlines MCRB Stock Analysis - Frequently Asked Questions How have MCRB shares performed this year? Seres Therapeutics' stock was trading at $14.88 at the beginning of the year. Since then, MCRB stock has decreased by 58.9% and is now trading at $6.11. How were Seres Therapeutics' earnings last quarter? Seres Therapeutics, Inc. (NASDAQ:MCRB) announced its quarterly earnings results on Tuesday, May, 5th. The biotechnology company reported ($2.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.88) by $0.20. The biotechnology company earned $0.36 million during the quarter, compared to analyst estimates of $0.36 million. When did Seres Therapeutics' stock split? Seres Therapeutics shares reverse split on the morning of Tuesday, April 22nd 2025.The 1-20 reverse split was announced on Thursday, April 10th 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 21st 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Seres Therapeutics IPO? Seres Therapeutics (MCRB) raised $119 million in an initial public offering (IPO) on Friday, June 26th 2015. The company issued 7,430,555 shares at a price of $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers. How do I buy shares of Seres Therapeutics? Shares of MCRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Seres Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Seres Therapeutics investors own include PayPal (PYPL), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Micron Technology (MU), Qualcomm (QCOM) and NIO (NIO). Company Calendar Last Earnings5/05/2026Today7/12/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 MCRB's financial health is in the Red zone, according to TradeSmith. MCRB has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MCRB CIK1609809 Webwww.serestherapeutics.com Phone(617) 945-9626FaxN/AEmployees330Year Founded2010Price Target and Rating Average Price Target for Seres Therapeutics$17.00 High Price Target$22.00 Low Price Target$12.00 Potential Upside/Downside+178.2%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($5.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$5.70 million Net MarginsN/A Pretax Margin-4,088.84% Return on Equity-130.29% Return on Assets-35.35% Debt Debt-to-Equity RatioN/A Current Ratio1.65 Quick Ratio1.65 Sales & Book Value Annual Sales$790 thousand Price / Sales74.87 Cash Flow$1.09 per share Price / Cash Flow5.62 Book Value$4.89 per share Price / Book1.25Miscellaneous Outstanding Shares9,680,000Free Float9,180,000Market Cap$59.14 million OptionableOptionable Beta0.09 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:MCRB) was last updated on 7/13/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seres Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seres Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
